---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-24-007877"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:32:20.291595+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro raises $400K via convertible preferred and short-term note

## Summary
- Sold 100 Series B preferred shares and warrants for 100K common shares to Ault Lending for $100K; total $2.1M of $6M facility drawn.
- Issued $310K face promissory note (15% interest, $10K OID) to Orchid Finance LLC; matures May 13, 2024.
- Note repayment guaranteed by Ault Lending and Milton C. Ault, Vice Chairman of Alzamend.
- Proceeds used for working capital; note matures in two weeks, creating near-term repayment risk.

## SEC filing metadata
- accession: 0001214659-24-007877
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/0001214659-24-007877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/g4302428k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-24-007877
- JSON: https://secwatch.observer/filing/0001214659-24-007877.json
- Plain text: https://secwatch.observer/filing/0001214659-24-007877.txt

## Key facts
- Debt Financings
  Alzamend Neuro, Inc. incurred loan of $310,000 with an accredited investor at fifteen percent (15%) per annum maturing May 13, 2024.
  - Instrument: loan
  - Principal: $310,000
  - Counterparty: an accredited investor
  - Rate: fifteen percent (15%) per annum
  - Maturity: May 13, 2024
  - Event: incurrence
  source text: Effective April 29, 2024, the Company issued to an accredited investor a term note (the “ Note ”) with a principal face amount of $310,000. The Note bears interest at the rate of fifteen percent (15%) per annum and the Note was issued with an original issuance discount. The maturity date of the Note is May 13, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/0001214659-24-007877-index.htm
- Material Agreements
  Alzamend Neuro, Inc. entered into the Note with an accredited investor valued at $310,000 (effective 2024-04-29).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: an accredited investor
  - Value: $310,000
  - Effective: 2024-04-29
  source text: Effective April 29, 2024, the Company issued to an accredited investor a term note (the “ Note ”) with a principal face amount of $310,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/0001214659-24-007877-index.htm
- Material Agreements
  Alzamend Neuro, Inc. entered into the Guaranty with Ault Lending (effective 2024-04-29).
  - Action: entry
  - Counterparty: Ault Lending
  - Effective: 2024-04-29
  source text: Ault Lending Additional Closing On April 29, 2024, Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”), pursuant to the Securities Purchase Agreement (the “ Agreement ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/0001214659-24-007877-index.htm
- Material Agreements
  Alzamend Neuro, Inc. entered into the Securities Purchase Agreement with Ault Lending, LLC valued at $2.1 million (effective 2024-01-31).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Ault Lending, LLC
  - Value: $2.1 million
  - Effective: 2024-01-31
  source text: lzamend Neuro, Inc., a Delaware corporation (the “ Company ”), pursuant to the Securities Purchase Agreement (the “ Agreement ”) entered into with Ault Lending, LLC, a California limited liability company (“ Ault Lending ”) on January 31, 2024, sold
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/0001214659-24-007877-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.